Crank et al reported promising results of a novel experimental respiratory syncytial virus (RSV) vaccine from a Phase 1 clinical trial. The vaccine contained stabilised prefusion DS-Cav1 molecule developed from a structure-based RSV fusion glycoprotein. The study analysed data from 40 healthy adult volunteers enrolled in the trial. The volunteers received a
dose of either 50 or 150 micrograms (µg) of the investigational vaccine. Four weeks after immunisation, the vaccine elicited substantially more high-quality antibody titres than those typically generated using earlier RSV
immunogens. A single dose of 150 µg without alum boosted neutralising antibody levels 12-fold, while alum-adjuvanted vaccine at that dose prompted a 15-fold surge in neutralising antibodies. Researchers showed that the RSV F-neutralising antibody level sustained 5 to 10-fold above the baseline levels for several months in all vaccine dosage groups. The findings provide a proof of concept for how structural biology can contribute to precision vaccine design.
Source: Science 02 Aug 2019: Vol. 365, Issue 6452, pp. 505-509 DOI: 10.1126/science.aav9033 https://science.sciencemag.org/content/365/6452/505